Factbox-A brief guide to the Catholic Church's saint-making process
VATICAN CITY (Reuters) - The Catholic Church will proclaim its first millennial saint on April 27, elevating Carlo Acutis, a teenage web developer who died from leukaemia in 2006, to the same status as Saint Francis and Mother Teresa.
Here is a brief summary of how the Roman Catholic Church recognises sainthood.
The process that can lead to sainthood, known as a "cause", cannot usually start until five years after a person's death.
In the early years of the Church, a saint could be declared such by acclamation by the people, or by cardinals, or by papal decree.
Today, the Vatican department that studies sainthood causes is known as the Dicastery for the Causes of Saints. Its origins date back to 1588, but the department has been modified several times over the years.
After the Dicastery accepts the name of a person to be considered for sainthood, that person is given the title "Servant of God".
If initial investigations show that the candidate for sainthood lived what is known as a life of "heroic virtues," that person is given the title "Venerable".
Historical and theological commissions in the Dicastery study the person's life, read his or her writings and interview people who knew the person.
At this point, in order for the procedure to continue, a miracle is needed.
Miracles are not performed by prospective saints but by God. The Church believes that, because a prospective saint is in heaven, he or she can intercede with God to perform the miracle for someone on earth who has prayed for the prospective saint's help.
A miracle is usually a medically inexplicable healing. A medical commission appointed by the Vatican determines if there was any medical explanation for the healing or not.
Miracles are not necessary if a person was a martyr, someone killed in what the Church calls "hatred of the faith".
If a miracle is determined for those who were not martyrs, the person can be "beatified" and is given the title "Blessed".
Carlo Acutis was beatified in 2020.
A second, distinct miracle must take place after the beatification in order to proceed to sainthood.
Acutis is credited with two miracles – the healing of a 4-year-old Brazilian boy with a serious pancreatic malformation and of a 21-year-old Costa Rican woman who was near death after a tragic bicycle accident.
The parents of both individuals had prayed to Acutis for help, Church authorities said.
Acutis himself was a believer in miracles. Shortly before his death, he finished developing a website to track locations of reported Catholic miracles around the world.
Other saints who died at a young age include St. Therese of Lisieux, who died at 24 in 1897 and was known for promoting a "Little Way" of love and charity; and St. Aloysius Gonzaga who died at 23 in 1591 after caring for victims of an epidemic in Rome.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Exclusive-UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say
By Tatiana Bautzer and Sabrina Valle NEW YORK (Reuters) -UnitedHealth Group is weighing multiple bids for its Latin American operations, according to two people with direct knowledge of the matter, as the insurer buckles down after a series of unprecedented missteps that include the ouster of its CEO and a reported criminal accounting probe. The largest U.S. health insurer has been trying to exit Latin America since 2022, but the sale of Banmedica has taken on increasing urgency in recent months as the insurer took hits on multiple fronts, according to one of the people. New CEO Steve Hemsley told shareholders last week that he was determined to earn back their trust after an earnings miss and a Wall Street Journal report that the company was under criminal investigation for alleged Medicare fraud. UnitedHealth has said it was not notified by the Department of Justice and that it stands by the integrity of its operations. Hemsley replaced Andrew Witty as CEO, who had been in the post for only a matter of months following the murder of his predecessor, Brian Thompson, in New York in December while on his way to a meeting with investors. The company has four non-binding bids for its Banmedica subsidiary, which operates in Colombia and Chile, for about $1 billion, according to both people, who asked not to be identified because the talks are private. UnitedHealth's shares tumbled 25.5% in May alone and year-to-date are down 40%. UnitedHealth left Brazil in 2023 and Peru in March. It's aiming to get around $1 billion for Banmedica's operations in Colombia and Chile, the people said. The two people said the company expects to set a deadline for binding proposals as soon as July. UnitedHealth received bids from Washington, D.C.-based private equity firm Acon Investments; Sao Paulo-based private equity firm Patria Investments; Texas non-profit health firm Christus Health; and Lima-based healthcare and insurance provider Auna, the people said. Auna is in talks with a financial partner, one of the sources added. Banmedica's annual earnings before income taxes, depreciation and amortization, or EBITDA, is more than $200 million a year. Patria and Christus Health declined to comment. UnitedHealth, Acon and Auna did not respond to requests for comment. FAILED EXPANSION PLANS UnitedHealth bought Banmedica in 2018, with CEO David Scott saying he was "establishing a foundation for growth in South America for the next decades." At the time, UnitedHealth paid around 12 times Banmedica's EBITDA, according to one of the people. Three years later, the insurer decided to leave Latin America as it grappled with losses in its largest operation in the region, Brazil's Amil, which had been acquired a decade earlier. It divested from its Brazilian operations in late 2023. Banmedica is currently profitable, but is considered too small by UnitedHealth. It serves over 2.1 million consumers through its health insurance programs and has around 4 million patient visits annually across its network of 13 hospitals and 143 medical centers. UnitedHealth booked an $8.3 billion loss last year related to the sale of its South American operations - $7.1 billion stemming from the Brazil exit and $1.2 billion from Banmedica. "These losses relate to our strategic exit of South American markets and include significant losses related to foreign currency translation effects," the company said in a February filing. Brazilian investment bank BTG Pactual is advising UnitedHealth on the sale.
Yahoo
11 hours ago
- Yahoo
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
Miami Herald
20 hours ago
- Miami Herald
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination What can contaminated swabs do? Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' Exactly which Orajel and Zicam swabs are recalled? ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. What should you do now? If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
